Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482088 | 0.88 | OPRL1 (0.53) | BCHEACHEBACE1EPHX2CYP2C9 | |
| SCHEMBL951933 | 0.83 | ALDH1A1 (0.57) | BCHEACHEBACE1EPHX2GRM2 | |
| SCHEMBL951932 | 0.83 | ALDH1A1 (0.57) | BCHEACHEBACE1EPHX2GRM2 | |
| SCHEMBL4485008 | 0.80 | P2RX7 (0.45) | BCHEACHEBACE1SIGMAR1 | |
| SCHEMBL4492750 | 0.79 | ENPP2 (0.45) | BCHEACHEBACE1EPHX2SIGMAR1 | |
| SCHEMBL15054550 | 0.79 | EPHX2 (0.49) | BCHEACHEBACE1EPHX2SIGMAR1 | |
| SCHEMBL4205757 | 0.78 | ALDH1A1 (0.59) | BCHEACHEBACE1EPHX2CYP2C9 | |
| SCHEMBL27701486 | 0.78 | KDM1A (0.50) | BCHEACHEBACE1EPHX2CYP2C9 | |
| SCHEMBL27722373 | 0.78 | KDM1A (0.50) | BCHEACHEBACE1EPHX2CYP2C9 | |
| SCHEMBL27722371 | 0.77 | KDM1A (0.49) | BCHEACHEBACE1EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1828122-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| WO-2006064351-A2 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | BCHE 1294/4885ACHE 393/4885BACE1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.